Storage solutions: Treating lysosomal disorders of the brain

Nature Reviews Neuroscience

Volumn 6, Issue 9, 2005, Pages 713-725

  Jeyakumar, Mylvaganam ^a   Dwek, Raymond A ^a   Butters, Terry D ^a   Platt, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GANGLIOSIDE GM1; SPHINGOLIPID;

ANIMAL; BIOLOGICAL MODEL; BRAIN; CELL MEMBRANE; HOMEOSTASIS; HUMAN; LYSOSOME STORAGE DISEASE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; REVIEW;

ANIMALS; BRAIN; CALCIUM; G(M1) GANGLIOSIDE; HOMEOSTASIS; HUMANS; LYSOSOMAL STORAGE DISEASES; MEMBRANE MICRODOMAINS; MODELS, BIOLOGICAL; PROTEIN TRANSPORT; SPHINGOLIPIDS;

EID: 25144442267     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1725     Document Type: Review

References (98)

1. Hamburger, V. Cell death in the development of the lateral motor column of the chick embryo. J. Comp. Neurol. 160, 535-546 (1975).
2. Prunell, G. F. & Troy, C. M. Balancing neuronal death. J. Neurosci. Res. 78, 1-6 (2004).
3. Przedborski, S., Vila, M. & Jackson-Lewis, V. Neurodegeneration: what is it and where are we? J. Clin. Invest. 111, 3-10 (2003).
4. Schulte, P. A., Burnett, C. A., Boeniger, M. F. & Johnson, J. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am. J. Public Health 86, 1281-1288 (1996).
5. Platt, F. M. & Walkley, S. U. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 32-49 (Oxford Univ. Press, Oxford, 2004).
6. Wraith, J. E. Lysosomal disorders. Semin. Neonatol. 7, 75-83 (2002).
7. Hopwood, J. J., Crawley, A. C. & Taylor, R. M. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 257-289 (Oxford Univ. Press, Oxford, 2004).
8. Rapola, J. Lysosomal storage diseases in adults. Pathol. Res. Pract. 190, 759-766 (1994).
9. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 281, 249-254 (1999). Currently the most comprehensive study of storage disease prevalence.
10. Dahl, N., Lagerstrom, M., Erikson, A. & Pettersson, U. Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am. J. Hum. Genet. 47, 275-278 (1990).
11. Ozkara, H. A. & Topcu, M. Sphingolipidoses in Turkey. Brain Dev. 26, 363-366 (2004).
12. Winchester, B. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 81-130 (Oxford Univ. Press, Oxford, 2004).
13. Beutler, E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc. Natl Acad. Sci. USA 90, 5384-5390 (1993).
14. Diamond, J. M. Jewish lysosomes. Nature 368, 291-292 (1994).
15. Beutler, E. et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am. J. Hum. Genet. 52, 85-88 (1993).
16. Hers, H. G. α-Glucosidase deficiency in generalised glycogen storage disease (Pompe's disease). Biochem. J. 86, 11-16 (1963).
17. Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nature Rev. Mol. Cell Biol. 5, 554-565 (2004).
18. Desnick, R. J., Thorpe, S. R. & Fiddler, M. B. Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56, 57-99 (1976).
19. Norflus, F. et al. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101, 1881-1888 (1998).
20. Andersson, U. et al. Improved outcome of N-butyldeoxygalactonojirimycin- mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 16, 506-515 (2004).
21. M2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum. Mol. Genet. 6, 1879-1885 (1997).
22. Walkley, S. U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 15, 433-444 (2004).
23. Selkoe, D. J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nature Cell Biol. 6, 1054-1061 (2004).
24. Klein, A. et al. Identification of urinary oligosaccharides by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin. Chem. 44, 2422-2428 (1998).
25. Beutler, E. & Grabowski, G. in The Metabolic and Molecular Bases of Inherited Diseases (ed. Sly, W. S.) 3636-3668 (McGraw Hill, New York, 2001).
26. Suzuki, K. The pattern of mammalian brain gangliosides - regional and developmental differences. J. Neurochem. 12, 969-979 (1965).
27. Overly, C. C. & Hollenbeck, P. J. Dynamic organization of endocytic pathways in axons of cultured sympathetic neurons. J. Neurosci. 16, 6056-6064 (1996).
28. Walkley, S. U. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 290-324 (Oxford Univ. Press, Oxford, 2004).
29. Walkley, S. U., Zervas, M. & Wiseman, S. Gangliosides as modulators of dendritogenesis in normal and storage disease - affected pyramidal neurons. Cereb. Cortex 10, 1028-1037 (2000).
30. Walkley, S. U., Siegel, D. A. & Dobrenis, K. GM2 ganglioside and pyramidal neuron dendritogenesis. Neurochem. Res. 20, 1287-1299 (1995).
31. Chiesa, R. et al. Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. Proc. Natl Acad. Sci. USA 102, 238-243 (2005).
32. Purpura, D. P., Highstein, S. M., Karabelas, A. B. & Walkley, S. U. Intracellular recording and HRP-staining of cortical neurons in feline ganglioside storage disease. Brain Res. 181, 446-449 (1980).
33. Karabelas, A. B. & Walkley, S. U. Altered patterns of evoked synaptic activity in cortical pyramidal neurons in feline ganglioside storage disease. Brain Res. 339, 329-336 (1985).
34. Chen, C. S., Patterson, M. C., Wheatley, C. L., O'Brien, J. F. & Pagano, R. E. Broad screening test for sphingolipid-storage diseases. Lancet 354, 901-905 (1999). The identification of a global trafficking defect in sphingolipid storage diseases.
35. Puri, V. et al. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nature Cell Biol. 1, 386-388 (1999).
36. Sillence, D. J. et al. Glucosylceramide modulates membrane traffic along the endocytic pathway. J. Lipid Res. 43, 1837-1845 (2002).
37. Golub, T., Wacha, S. & Caroni, P. Spatial and temporal control of signaling through lipid rafts. Curr. Opin. Neurobiol. 14, 542-550 (2004).
38. Sharma, D. K. et al. Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling. J. Biol. Chem. 278, 7564-7572 (2003).
39. Gruenberg, J. The endocytic pathway: a mosaic of domains. Nature Rev. Mol. Cell Biol. 2, 721-730 (2001).
40. Sharma, P., Sabharanjak, S. & Mayor, S. Endocytosis of lipid rafts: an identity crisis. Semin. Cell Dev. Biol. 13, 205-214 (2002).
41. Dermine, J. F. et al. Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes. J. Biol. Chem. 276, 18507-18512 (2001).
42. Bagshaw, R. D., Mahuran, D. J. & Callahan, J. W. A proteomic analysis of lysosomal integral membrane proteins reveals the diverse composition of the organelle. Mol. Cell. Proteomics 4, 133-143 (2005).
43. Pagano, R. E., Puri, V., Dominguez, M. & Marks, D. L. Membrane traffic in sphingolipid storage diseases. Traffic 1, 807-815 (2000).
44. Simons, K. & Gruenberg, J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol. 10, 459-462 (2000). A review that proposes the raft hypothesis of lysosomal storage diseases.
45. Zervas, M., Somers, K. L., Thrall, M. A. & Walkley, S. U. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 11, 1283-1287 (2001).
46. Berridge, M. J., Bootman, M. D. & Roderick, H. L. Calcium signalling: dynamics, homeostasis and remodelling. Nature Rev. Mol. Cell Biol. 4, 517-529 (2003).
47. Korkotian, E. et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274,21673-21678 (1999). The first study to implicate defects in calcium homeostasis in a lysosomal storage disease.
48. Lloyd-Evans, E. et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 278, 23594-23599 (2003).
49. Pelled, D. et al. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18, 83-88 (2005).
50. 2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem. 278, 29496-29501 (2003).
51. Ginzburg, L., Kacher, Y. & Futerman, A. H. The pathogenesis of glycosphingolipid storage disorders. Semin. Cell Dev. Biol. 15, 417-431 (2004).
52. Bezprozvanny, I. & Hayden, M. R. Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310-1317 (2004).
53. Mandel, S. et al. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762 (2003).
54. Albin, R. L. Dominant ataxias and Friedreich ataxia: an update. Curr. Opin. Neurol. 16, 507-514 (2003).
55. Ho, R., Ortiz, D. & Shea, T. B. Amyloid-β promotes calcium influx and neurodegeneration via stimulation of L voltage-sensitive calcium channels rather than NMDA channels in cultured neurons. J. Alzheimers Dis. 3, 479-483 (2001).
56. Kawahara, M. & Kuroda, Y. Molecular mechanism of neurodegeneration induced by Alzheimer's β-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53, 389-397 (2000).
57. Tessitore, A. et al. G(M1)-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15, 753-766 (2004). The first study to show an unfolded protein response in a storage disease.
58. Forman, M. S., Lee, V. M. & Trojanowski, J. Q. 'Unfolding' pathways in neurodegenerative disease. Trends Neurosci. 26, 407-410 (2003).
59. Ryu, E. J. et al. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 22, 10690-10698 (2002).
60. Imaizumi, K. et al. The unfolded protein response and Alzheimer's disease. Biochim. Biophys. Acta 1536, 85-96 (2001).
61. Kudo, T. et al. The unfolded protein response is involved in the pathology of Alzheimer's disease. Ann. NY Acad. Sci. 977, 349-355 (2002).
62. Ron, D. & Oyadomari, S. Lipid phase perturbations and the unfolded protein response. Dev. Cell 7, 287-288 (2004).
63. McGeer, E. G. & McGeer, P. L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 741-749 (2003).
64. Streit, W. J. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77, 1-8 (2004).
65. Tuppo, E. E. & Arias, H. R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37, 289-305 (2005).
66. McGeer, P. L. & McGeer, E. G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470 (2002).
67. McGeer, P. L. & McGeer, E. G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10 (Suppl. 1), S3-S7 (2004).
68. Perry, V. H., Cunningham, C. & Boche, D. Atypical inflammation in the central nervous system in prion disease. Curr. Opin. Neurol. 15, 349-354 (2002).
69. Perry, V. H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav. Immun. 18, 407-413 (2004). A comprehensive review of how stimulation of the peripheral immune system can exacerbate inflammation in the CNS in neurodegenerative diseases.
70. Jeyakumar, M. et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126, 974-987 (2003).
71. Myerowitz, R. et al. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. 11, 1343-1350 (2002).
72. Wada, R., Tifft, C. J. & Proia, R. L. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is supressed by bone marrow transplantation. Proc. Natl Acad. Sci. USA 97, 10954-10959 (2000). The first demonstration of a potentially causative role of microglia in the disease pathogenesis of a ganglioside storage disorder.
73. Baudry, M., Yao, Y., Simmons, D., Liu, J. & Bi, X. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol. 184, 887-903 (2003).
74. LeVine, S. M. & Brown, D. C. IL-6 and TNFα expression in brains of twitcher, quaking and normal mice. J. Neuroimmunol. 73, 47-56 (1997).
75. Pedchenko, T. V. & LeVine, S. M. IL-6 deficiency causes enhanced pathology in twitcher (globoid cell leukodystrophy) mice. Exp. Neurol. 158, 459-468 (1999).
76. Fadok, V. A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890-898 (1998).
77. Neufeld, E. F. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 327-338 (Oxford Univ. Press, Oxford, 2004).
78. Brady, R. O. Enzyme replacement therapy: conception, chaos and culmination. Phil. Trans. R. Soc. Lond. B 358, 915-919 (2003). A review of the history of the challenges involved in and the ultimate success of developing effective ERT for type 1 Gaucher disease.
79. Campbell, P. E., Harris, C. M. & Vellodi, A. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology 63, 385-387 (2004).
80. Erikson, A., Bembi, B. & Schiffmann, R. Neuronopathic forms of Gaucher's disease. Baillieres Clin. Haematol. 10, 711-723 (1997).
81. Wraith, J. E. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 50-77 (Oxford Univ. Press, Oxford, 2004).
82. Dobrenis, K. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 339-380 (Oxford Univ. Press, Oxford, 2004).
83. Sands, M. S. in Lysosomal Disorders of the Brain (eds. Platt, F. M. & Walkley, S. U.) 409-430 (Oxford Univ. Press, Oxford, 2004).
84. Conzelmann, E. & Sandhoff, K. Biochemical basis of late-onset neurolipidoses. Dev. Neurosci. 13, 197-204 (1991). A seminal theoretical paper defining the threshold hypothesis of storage that explains the differential rate of the clinical onset of symptoms.
85. Snyder, E. Y., Daley, G. Q. & Goodell, M. Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J. Neurosci. Res. 76, 157-168 (2004).
86. Vunnam, R. R. & Radin, N. S. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids 26, 265-278 (1980).
87. Radin, N. S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13, 153-157 (1996).
88. Platt, F. M. & Butters, T. D. in Lysosomal Disorders of the Brain (eds Platt, F. M. & Walkley, S. U.) 381-408 (Oxford Univ. Press, Oxford, 2004).
89. Liu, Y. et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 103, 497-505 (1999).
90. Winchester, B. & Fleet, G. W. Amino-sugar glycosidase inhibitors: versatile tools for glycobiologists. Glycobiology 2, 199-210 (1992).
91. Fischer, P. B. et al. The α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69, 5791-5797 (1995).
92. 3. J. Acquir. Immune Defic. Syndr. 7, 139-147 (1994).
93. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365 (1994).
94. Cox, T. et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485 (2000). The first demonstration of clinical efficacy of SRT in patients with type 1 Gaucher disease.
95. Lachmann, R. H. Miglustat. Oxford GlycoSciences/ Actelion. Curr. Opin. Investig. Drugs 4, 472-479 (2003).
96. Sango, K. et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11, 170-176 (1995).
97. Jeyakumar, M. et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 6388-6393 (1999).
98. Platt, F. M. et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431 (1997).